| Year |
Citation |
Score |
| 2023 |
Degrave R, Murris J, Charles-Nelson A, Hermine O, Porcher R, Ravaud P, Mariette X, Tharaux PL, Resche-Rigon M, Sanchez O, Katsahian S, Arlet JB. Risk factors for thromboembolic events in patients hospitalized for COVID-19 pneumonia in a general ward and requiring treatment with oxygen. Postgraduate Medical Journal. PMID 37978265 DOI: 10.1093/postmj/qgad104 |
0.447 |
|
| 2020 |
Murray TA, Thall PF, Schortgen F, Asfar P, Zohar S, Katsahian S. Robust Adaptive Incorporation of Historical Control Data in a Randomized Trial of External Cooling to Treat Septic Shock. Bayesian Analysis. 16: 825-844. PMID 36277025 DOI: 10.1214/20-ba1229 |
0.544 |
|
| 2020 |
Letestu R, Dahmani A, Boubaya M, Baseggio L, Campos L, Chatelain B, Debliquis A, Drénou B, Jacob MC, Legac E, Le Garff-Tavernier M, Lhoumeau AC, Quiney C, Robillard N, Ticchioni M, ... ... Katsahian S, et al. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia. Leukemia. PMID 32934355 DOI: 10.1038/S41375-020-01009-Z |
0.562 |
|
| 2020 |
Etienne G, Dulucq S, Bauduer F, Adiko D, Lifermann F, Dagada C, Lenoir C, Schmitt A, Klein E, Madene S, Fort MP, Bijou F, Moldovan M, Turcq B, Robbesyn F, ... ... Katsahian S, et al. Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients. Cancers. 12. PMID 32899879 DOI: 10.3390/Cancers12092521 |
0.33 |
|
| 2020 |
Murray TA, Thall PF, Schortgen F, Zohar S, Katsahian S. Robust Adaptive Incorporation of Historical Control Data in a Randomized Trial of External Cooling to Treat Septic Shock Bayesian Analysis. DOI: 10.1214/20-Ba1229 |
0.564 |
|
| 2020 |
Diao G, Vidyashankar AN, Zohar S, Katsahian S. Competing Risks Model with Short-Term and Long-Term Covariate Effects for Cancer Studies Statistics in Biosciences. 1-18. DOI: 10.1007/S12561-020-09288-X |
0.582 |
|
| 2016 |
Verga-Gérard A, Mathoulin-Pélissier S, Chauvin F, Huiart L, Katsahian S, Nacher M, Alberti C, Binquet C, Fourrier-Réglat A, Bellisant E, Giraudeau B, Lapeyre-Mestre M, Tubach F, Guillemin F. RECaP : réseau national de recherche en épidémiologie clinique et en santé publique Revue D'éPidéMiologie Et De Santé Publique. 64: S160-S161. DOI: 10.1016/J.Respe.2016.03.107 |
0.361 |
|
| 2014 |
Pibouleau L, Galtier T, Sailly AC, Maison P, Katsahian S. Development of A Web-Based Tool To Elicit the Opinion of Regionally Dispersed Health Care Professionals Responsible for Medical Device Vigilance. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 17: A578. PMID 27201944 DOI: 10.1016/j.jval.2014.08.1953 |
0.674 |
|
| 2013 |
Dogan C, Hamroun D, Katsahian S, Fabbro M, French M, Quebec M, Eymard B, Puymirat J, Bassez G. P.18.1 The DM-Scope registry: Interfacing myotonic dystrophy clinical care and research Neuromuscular Disorders. 23: 832. DOI: 10.1016/J.Nmd.2013.06.670 |
0.331 |
|
| 2011 |
Zohar S, Katsahian S, O'Quigley J. An approach to meta-analysis of dose-finding studies. Statistics in Medicine. 30: 2109-16. PMID 21344473 DOI: 10.1002/Sim.4121 |
0.572 |
|
| 2011 |
Letestu R, Leprêtre S, Arnoulet C, Baseggio L, Campos L, Chatelain B, Drenou B, Jacob M, Legac E, Garff-Tavernier ML, Robillard N, Ticchioni M, Delepine R, Levy V, Katsahian S, et al. Interest of Early Determination of Bone Marrow MRD by a Sensitive 6-Color Flow Cytometry in the Evaluation of Response: The Experience of the CLL2007FMP, An Intergroup Phase III Randomized Multicentric Trial Comparing Fludarabine Cyclophosphamide (FC) and Rituximab (FCR) Versus FC and MabCampath (FCCam) in Previously Untreated B-Chronic Lymphocytic Leukemia Patients Blood. 118: 1797-1797. DOI: 10.1182/Blood.V118.21.1797.1797 |
0.557 |
|
| 2011 |
Letestu R, Leprêtre S, Arnoulet C, Baseggio L, Campos L, Chatelain B, Drenou B, Jacob M, Legac E, Garff-Tavernier ML, Ticchioni M, Robillard N, Delepine R, Levy V, Katsahian S, et al. 5.38 Interest of Early Determination of Bone Marrow Minimal Residual Disease by a Sensitive 6-Color Flow Cytometry in the Evaluation of Response: the Experience of the CLL2007FMP, an Intergroup Phase III Randomized Multicentric Trial Comparing Fludarabine, Cyclophosphamide, and Rituximab versus Fludarabine, Cyclophosphamide, and MabCampath in Previously Untreated B-Chronic Lymphocytic Leukemia Patients Clinical Lymphoma, Myeloma & Leukemia. 11. DOI: 10.1016/J.Clml.2011.09.192 |
0.557 |
|
| 2010 |
Gajdos V, Katsahian S, Beydon N, Abadie V, de Pontual L, Larrar S, Epaud R, Chevallier B, Bailleux S, Mollet-Boudjemline A, Bouyer J, Chevret S, Labrune P. Effectiveness of chest physiotherapy in infants hospitalized with acute bronchiolitis: a multicenter, randomized, controlled trial. Plos Medicine. 7: e1000345. PMID 20927359 DOI: 10.1371/Journal.Pmed.1000345 |
0.413 |
|
| 2010 |
Letestu R, Lévy V, Eclache V, Baran-Marszak F, Vaur D, Naguib D, Schischmanoff O, Katsahian S, Nguyen-Khac F, Davi F, Merle-Béral H, Troussard X, Ajchenbaum-Cymbalista F. Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters. Blood. 116: 4588-90. PMID 20739656 DOI: 10.1182/Blood-2010-06-288274 |
0.559 |
|
| 2008 |
Katsahian S, Latouche A, Mary JY, Chevret S, Porcher R. Practical methodology of meta-analysis of individual patient data using a survival outcome. Contemporary Clinical Trials. 29: 220-30. PMID 17884735 DOI: 10.1016/J.Cct.2007.08.002 |
0.675 |
|
| 2006 |
Katsahian S, Resche-Rigon M, Chevret S, Porcher R. Analysing multicentre competing risks data with a mixed proportional hazards model for the subdistribution. Statistics in Medicine. 25: 4267-78. PMID 16960919 DOI: 10.1002/Sim.2684 |
0.601 |
|
| 2006 |
Florent M, Katsahian S, Vekhoff A, Levy V, Rio B, Marie JP, Bouvet A, Cornet M. Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. The Journal of Infectious Diseases. 193: 741-7. PMID 16453271 DOI: 10.1086/500466 |
0.516 |
|
| 2006 |
Tournoux C, Katsahian S, Chevret S, Levy V. Factors influencing inclusion of patients with malignancies in clinical trials. Cancer. 106: 258-70. PMID 16397866 DOI: 10.1002/cncr.21613 |
0.591 |
|
| 2006 |
Katsahian S, Labopin M, Frassoni F, Rocha V, Chevret S. Persistent Centre Effect but Improvement of Leukemia-Free Survival of HLA Identical Hematopoietic Stem Cell Transplantation for Adults with AML in First CR in Europe over the Period 1987–2005 an Analysis on Behalf of the ALWP of EBMT. Blood. 108: 3027-3027. DOI: 10.1182/Blood.V108.11.3027.3027 |
0.472 |
|
| 2005 |
Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 9227-33. PMID 16275936 DOI: 10.1200/Jco.2005.03.0551 |
0.465 |
|
| 2005 |
Lévy V, Katsahian S, Fermand JP, Mary JY, Chevret S. A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy. Medicine. 84: 250-60. PMID 16010209 DOI: 10.1097/01.Md.0000173272.71949.A1 |
0.635 |
|
| 2004 |
Katsahian S, Porcher R, Mary JY, Chevret S. The graft-versus-leukaemia effect after allogeneic bone-marrow transplantation: assessment through competing risks approaches. Statistics in Medicine. 23: 3851-63. PMID 15580602 DOI: 10.1002/Sim.1999 |
0.461 |
|
| 2004 |
Cornet M, Katsahian S, Vekhoff A, Levy V, Rio B, Marie J, Bouvet A, Florent M. Early Diagnosis of Invasive Aspergillosis in Hematological Patients Using a PCR-ELISA Assay: A Prospective Validation. Blood. 104: 3833-3833. DOI: 10.1182/Blood.V104.11.3833.3833 |
0.551 |
|
| 2002 |
Porcher R, Lévy V, Fermand JP, Katsahian S, Chevret S, Ravaud P. Evaluating high dose therapy in Multiple Myeloma: use of quality-adjusted survival analysis. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 11: 91-9. PMID 12018742 DOI: 10.1023/A:1015096313594 |
0.595 |
|
| Show low-probability matches. |